VGX-3100 Elicits Regression and Clearance in HPV-16/18–Associated Cervical HSILs
Inovio's VGX-3100 immunotherapy showed significant improvement in HPV-16/18-associated cervical HSILs in a phase 3 trial. At week 36, 52.5% of patients in the VGX-3100 arm achieved histologic regression with HPV clearance vs 35.3% in the placebo arm. The treatment was well-tolerated with no serious adverse effects. Inovio's stock may be impacted by these trial results.
How this was made
The 30-second read
Why it matters
The data provide the first pivotal efficacy readout for a non-surgical HPV therapeutic, potentially expanding Inovio's pipeline value.
Market read
Positive trial results could drive INO stock higher and influence the broader DNA vaccine sector.
What to watch
Regulatory pathway and reimbursement uncertainties could temper upside.
Background
Inovio Pharmaceuticals presented phase 3 data for VGX-3100 at the 2026 SITC meeting, following FDA accelerated approval of a related DNA therapy.
Ticker impact
Phase 3 VGX-3100 trial shows statistically significant improvement in HPV-16/18 clearance versus placebo.
upward pressure as market prices in the efficacy advantage.
Statistically significant efficacy and safety data are new and material for a biotech with no prior approval.
Market effects
May boost confidence in DNA immunotherapy platforms and could lift peers in the biotech immunotherapy space.
Limited to US biotech sector; no broader regional effect.
Highlights progress in HPV therapeutic vaccines, relevant to global health investors.
Counterpoint
Skeptics may question long-term durability of response and commercial viability.
Key entities
- companyInovio Pharmaceuticals
US biotech developing DNA immunotherapies, ticker INO.
- productVGX-3100
Investigational DNA immunotherapy targeting HPV-16/18.
